Davide Bonazzi
Illustrator
From this contributor
Company on brink takes psilocybin to trial for fragile X syndrome
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
Company on brink takes psilocybin to trial for fragile X syndrome
Explore more from The Transmitter
Not playing around: Why neuroscience needs toy models
Amid the rise of billion-parameter models, I argue that toy models, with just a few neurons, remain essential—and may be all neuroscience needs.
Not playing around: Why neuroscience needs toy models
Amid the rise of billion-parameter models, I argue that toy models, with just a few neurons, remain essential—and may be all neuroscience needs.
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
Psychedelics research in rodents has a behavior problem
Simple behavioral assays—originally validated as drug-screening tools—fall short in studies that aim to unpack the psychedelic mechanism of action, so some behavioral neuroscientists are developing more nuanced tasks.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.
New organoid atlas unveils four neurodevelopmental signatures
The comprehensive resource details data on microcephaly, polymicrogyria, epilepsy and intellectual disability from 352 people.